U
UBI
vs
S
S&P/ASX 300
Over the past 12 months, UBI has underperformed S&P/ASX 300, delivering a return of -87% compared to the S&P/ASX 300's +7% growth.
Stocks Performance
UBI vs S&P/ASX 300
Performance Gap
UBI vs S&P/ASX 300
Performance By Year
UBI vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Universal Biosensors Inc
Glance View
Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, COVID-19, women’s health and fertility, non-human and environmental testing using its patented platform technology and hand-held point of use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system using opposing electrodes that detects specific analytes in samples as small as a droplet. Its products include Sentia, a wine analyzer, and Xprecia Prime, a coagulation analyzer. Its Hemostasis Reference Laboratory Meso Scale Discovery (MSD) multiplex platform couples immunoassay methodology with electrochemiluminescence (ECL) detection to provide measurement of a multitude of different cytokine panels. Its laboratory services include assay validation and analysis and consultation for study design.
